No difference in skin cancer incidence with or without cyclosporine--a 5-year perspective.
In the short perspective of 5 years, there was no difference in the incidence of malignant and premalignant skin lesions among patients with Aza- vs CyA-based immunosuppressive protocols, or when these drugs were combined. However, the risk of acquiring skin cancer increases with the length of immunosuppressive therapy. Another 5 to 10 years of experience with CyA will be needed to decide on any change in the established pattern of posttransplant skin complications.